In 2018, the Rao group pioneered the development of a PROTAC molecule, designated as compound 3, which was shown to induce PARP1 cleavage and cell apoptosis in the MDA-MB-231 breast cancer cell line [38]. The gene discussed is PARP1; the disease is breast cancer.